fashion -WSS

fashion

author：focus 2025-09-30 00:47:19 - browse：6213

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Covid’s new normal has set in amid another rise in cases

knowledge

WSS

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

People with substance use disorder deserve online privacy

Why the quest to eradicate polio has stumbled

Longer MASH drug regimen improved liver, Akero study finds

Assistant physicians can help address the primary care shortage

Medicare drug price negotiation continues, as pharma counteroffers

knowledge

fashion

explore

Novavax promises a turnaround & Lilly roils the obesity market

Florida health officials providing scant details on measles cases

DIEP, the 'gold standard' of breast reconstruction, is under threat

David Liu startup to focus on CRISPR delivery

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Cancer drug shortages should be causing more outrage

Information blocking fines are now fair game in health care

Medical leaders decry Supreme Court decision on affirmative action

Midwives could help bridge maternal health disparities in the U.S.

Wikipedia

Midwives could help bridge maternal health disparities in the U.S.

Change Healthcare: What is it, why does its cyberattack matter?

'A game

House panel takes first step toward fixing drug shortages

Why Talkspace is targeting Medicare, a tricky market

Patients, doctors press FTC to beef up hospital merger scrutiny

hotspot

knowledge

focus

hotspot